EUVIMEDEUVIMED entdecken
Editorial

Personalized tapering of tumor necrosis factor inhibitor in axial spondyloarthritis

Jin-Xian Huang iD, Yung-Heng Lee, Pui-Ying Leong iD, James Cheng-Chung Wei iD

International Journal of Rheumatic Diseases · 2024

DOI: 10.1111/1756-185x.15008 ↗

Kurz gefasst

Editorial in der Zeitschrift International Journal of Rheumatic Diseases, 2024. Verfasst von Jin-Xian Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China. Hauptthemen laut MEDLINE: Antirheumatic Agents, Axial Spondyloarthritis, Spondylarthritis, Spondylitis, Ankylosing. Die Arbeit nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tapering of biologics can be considered in patients with axial spondyloarthritis (axSpA) in sustained remission in the most updated ASAS-EULAR recommendations in 2022.1 Tumor necrosis factor inhibitor (TNFi) has been widely used for decades for the treatment of axSpA after nonsteroid anti-inflammatory drugs(NSAIDs) failure. Although the criteria to follow for the start of tapering and the impact of tapering on structural damage are still in research agenda, consensus has been drawn in core issues concerning tapering of TNFi. The definition of “sustained remission” has been introduced in 2016 in the previous ASAS-EULAR recommendations to be at least 6 months and possibly longer in remission of disease activity in axSpA.2 Consensus from Spanish Rheumatology Society also stated the same timing for biologics-tapering initiation after therapeutic goal was achieved and maintained.3 From our perspective,4 at least 6–12 months of remission and no radiographical progression must be obtained before decrease in biological dosing or intervals.4 Timing of tapering biologics should be personalized and flexible. For instance, individuals with unfavorable factors, such as high disease activity indexes, poor patient-reported outcomes (PROs), and rapid progression in imaging, remission should be maintained for longer time. For those with comorbidities, such as uveitis and inflammatory bowel disease (IBD), relevant guidelines could be followed and timing of tapering TNFi could be prolonged to 1–2 years for better prognosis.5, 6 In uveitis, de-escalation of treatment should be preceded by period of at least 2 years of disease inactivity.6 In IBD, dose de-escalation of biologics would be preferred in a state of deep remission [clinical, biological, and endoscopic remission] and with drug trough level remaining within an appropriate target window.6 Difficult-to-Treat (D2T) concept has not been elaborated in axSpA and would be considered in the decision-making of tapering.7 Disease activity-guided (DAG) tapering approach seemed to be favored over fixed dose approach in the real-world setting. In a retrospective study enrolled with 171 axSpA patients followed up for 44 months, DAG dose optimization with calculated daily defined dose (%DDD) of 62% had no negative impact on disease activity compared with full dose implementation.8 Another real-world retrospective study9 enrolled 108 patients with ankylosing spondylitis (AS) treated with TNFi biosimilar for more than 1 year also concluded that DAG stepwise tapering with reduced drug exposure is a feasible therapeutic strategy. Tapering intensity was recommended to be 20%–50% reduction initially by dose reduction or increased spacing.3 Together with evidence from real-world studies, we suggest a gradual tapering of 25% every 3–6 months without exceeding 50% of the initial dose each time.10 Tapering would probably lead to discontinuation ultimately in minority of patients, while we believe the maintenance with minimal dosage or intervals would be a preferred strategy to achieve the treat-to-target overall principles. In summary, the best care should be implemented through shared decision-making between physicians and patients to achieve personalized optimization of tapering approach. Cost-effectiveness, safety, efficacy, and convenience should all be taken into account throughout the tapering process. It is anticipated that personalized tapering would be applicable to biologics with other targets in the future recommendations with upcoming evidence from the clinical trials. Jin-Xian Huang wrote the manuscript and Yung-Heng Lee was responsible for theoretical foundation and expertise in synthesizing existing knowledge. Pui-Ying Leong and James Cheng-Chung Wei took the lead in designing and conducting the manuscript.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsAxial SpondyloarthritisSpondylarthritisSpondylitis, AnkylosingHumansTumor Necrosis Factor InhibitorsAdalimumabTumor Necrosis Factor-alpha

Substanzen

Tumor Necrosis Factor InhibitorsAntirheumatic AgentsAdalimumabTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China.
  • Department of senior services industry management, Minghsin University of Science and Technology, Hsinchu, Taiwan.
  • Department of Recreation and Sport Management, Shu-Te University, Kaohsiung, Taiwan.
  • Department of Orthopedics, Cishan Hospital, Ministry of Health and Welfare, Kaohsiung, Taiwan.
  • Division of of Allergy, Immunology & Rheumatology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.

ORCID-Profile: Jin-Xian Huang, Pui-Ying Leong, James Cheng-Chung Wei

Zitieren

APA

Huang, J. X., Lee, Y. H., Leong, P. Y., & Wei, J. C. (2024). Personalized tapering of tumor necrosis factor inhibitor in axial spondyloarthritis. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.15008

Vancouver

Huang JX, Lee YH, Leong PY, Wei JC. Personalized tapering of tumor necrosis factor inhibitor in axial spondyloarthritis. International Journal of Rheumatic Diseases. 2024. doi:10.1111/1756-185x.15008

BibTeX
@article{Huang2024,
  author = {Huang, Jin-Xian and Lee, Yung-Heng and Leong, Pui-Ying and Wei, James Cheng-Chung},
  title = {Personalized tapering of tumor necrosis factor inhibitor in axial spondyloarthritis},
  journal = {International Journal of Rheumatic Diseases},
  year = {2024},
  doi = {10.1111/1756-185x.15008}
}
Kostenlos starten →